NCT00048152 - A Study to Assess Use of Zenapax (Daclizumab) and CellCept (Mycophenolate Mofetil) to Improve Kidney Function in Kidney Transplant Patients | Biotech Hunter

Enrollment

539

Participants

Timeline

Start Date

December 31, 2000

Primary Completion Date

March 31, 2006

Study Completion Date

March 31, 2006

Conditions

Kidney Transplantation

Interventions

DRUG

Corticosteroids

As prescribed

DRUG

Neoral

Low dose (target trough level 50-100ng/mL)

DRUG

Neoral

Standard dose (target trough level 150-300ng/mL)

DRUG

Zenapax

2mg/kg iv first dose, then 1mg/kg every 2 weeks

DRUG

mycophenolate mofetil [CellCept]

1g po bid

Trial Locations (36)

1070

Brussels

2050

Sydney

3000

Leuven

5011

Adelaide

13353

Berlin

14004

Córdoba

20502

Malmo

29010

Málaga

30322

Atlanta

30625

Hanover

32610

Gainesville

35294

Birmingham

39008

Santander

41345

Gothenburg

46009

Valencia

48149

Münster

54511

Vandœuvre-lès-Nancy

94143

San Francisco

07039

Livingston

19102-1192

Philadelphia

29425-0777

Charleston

22042-3300

Falls Church

T2N 2T9

Calgary

T6G 2R8

Edmonton

V6Z 1Y6

Vancouver

S7N 0W8

Saskatoon

06720

Mexico City

Monterrey

0027

Oslo

02-006

Warsaw

50-417

Wroclaw

08036

Barcelona

08907

Barcelona

B15 2TH

Birmingham

G11 6NT

Glasgow

LE5 4PW

Leicester

All Listed Sponsors

lead

Hoffmann-La Roche

INDUSTRY